S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
LON:DXRX

Diaceutics (DXRX) Share Price, News & Analysis

GBX 104
0.00 (0.00%)
(As of 04/17/2024 ET)
Today's Range
103.25
104
50-Day Range
93.50
107
52-Week Range
79
110
Volume
29,645 shs
Average Volume
62,351 shs
Market Capitalization
£88.07 million
P/E Ratio
10,500.00
Dividend Yield
N/A
Price Target
GBX 150
DXRX stock logo

About Diaceutics Stock (LON:DXRX)

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX lab education, a suite of tailored and targeted training sessions designed to provide essential education for labs to enable and drive quality testing and biomarker knowledge; DXRX advisory boards that create and enable a valuable interface for pharmaceutical companies with a view to exploring and revealing new insights pertinent to the commercialisation and development of a therapy or companion diagnostic; and DXRX Lab Alerts, an advanced laboratory targeting service delivering tailored, short-form, quick read, educational messages with call-to-action to labs in the DXRX network. In addition, it offers implementation and consulting services for precision medicine diagnostics. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.

DXRX Stock Price History

DXRX Stock News Headlines

Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Diaceutics PLC (DXRX.L)
See More Headlines
Receive DXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Phone
N/A
Fax
N/A
Employees
151
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 150
High Stock Price Target
GBX 150
Low Stock Price Target
GBX 150
Potential Upside/Downside
+44.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£21.90 million
Cash Flow
GBX 33.34 per share
Book Value
GBX 49 per share

Miscellaneous

Free Float
N/A
Market Cap
£88.07 million
Optionable
Not Optionable
Beta
0.42
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Ryan Keeling (Age 42)
    CEO & Director
    Comp: $334.27k
  • Mr. Peter Keeling (Age 64)
    Founder & Executive Director
    Comp: $363.24k
  • Mr. Nicholas Stewart Roberts (Age 42)
    CFO & Director
    Comp: $180.37k
  • Ms. Julie Browne
    Chief Operating Officer
  • Ms. Gillian Shaw
    General Counsel
  • Ms. Norma Thompson
    Global Head of Human Resources
  • Mr. Jordan Clark
    Chief Commercial Officer
  • Ms. Susanne Munksted
    Chief Precision Medicine Officer
  • Ms. Jillian Beggs
    Chief Commercial Officer
  • Ms. Marieke Hoefsmit
    Senior Director & Head of Data Delivery Netherlands

DXRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Diaceutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diaceutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DXRX shares.
View DXRX analyst ratings
or view top-rated stocks.

What is Diaceutics' stock price target for 2024?

2 equities research analysts have issued twelve-month price objectives for Diaceutics' stock. Their DXRX share price targets range from GBX 150 to GBX 150. On average, they predict the company's share price to reach GBX 150 in the next year. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for DXRX
or view top-rated stocks among Wall Street analysts.

How have DXRX shares performed in 2024?

Diaceutics' stock was trading at GBX 87 on January 1st, 2024. Since then, DXRX shares have increased by 19.5% and is now trading at GBX 104.
View the best growth stocks for 2024 here
.

How do I buy shares of Diaceutics?

Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:DXRX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners